Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
Year: 2001
Type: article
Authors: Andrew J Barker, Keith H Gibson, Walter Grundy, Andrew A Godfrey, Jeffrey J Barlow, Mark P Healy, James R Woodburn, Susan E Ashton, Brenda J Curry, Lynn Scarlett, Lianne Henthorn, Laura Richards
Institution: AstraZeneca (United Kingdom)
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2062366098